LEADING RESEARCHERS SHARE IMPORTANT NEW FINDINGS ON THE MANAGEMENT OF BLEEDING DISORDERS AND OF BLOOD THINNERS DURING SURGERY
AT ISTH 2015 CONGRESS IN TORONTO, CANADA
ISTH Congress President Sam Schulman evaluates perioperative management of dabigatran; seeks to keep patient’s risk of thrombotic complications low with specified protocol
TORONTO – June 15, 2015 – The International Society of Thrombosis and Haemostasis (ISTH) 2015 XXV Congress sets the stage for thousands of the world’s leading experts in thrombosis, hemostasis and vascular biology to present recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care. Congress President and McMaster University Professor of Medicine Sam Schulman, along with Thomas Ortel, Professor of Medicine and Pathology, Duke University, and Charles V. Pollack, Jr., Professor of Emergency Medicine, University of Pennsylvania, and Chair, Department of Emergency Medicine, Pennsylvania Hospital, will present their cohort studies at the official ISTH press briefing on Tuesday, June 23 at 9 a.m. at the Metro Toronto Convention Centre.
Schulman’s research entitled, “Perioperative Management of Dabigatran: A Prospective Cohort Study,” Ortel’s study, “Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (The Bridge Trial),” and Pollack’s study, “Initial Results of the RE-VERSE AD Study: Idarucizumab Reverses the Anticoagulant Effects of Dabigatran in Patients in an Emergency Setting of Major Bleeding, Urgent Surgery or Interventions” impacts the more than three million Americans who qualify for blood-thinning drugs.
Thrombosis is the cause of the three biggest killers – heart attacks, stroke and pulmonary embolism. The Congress features medical experts from around the globe who are leading the charge in the research and treatment of clotting and bleeding disorders as well as thrombotic events like venous thromboembolism (VTE) (which includes deep vein thrombosis and pulmonary embolism), myocardial infarction and stroke.
Researchers will present their studies throughout the Congress beginning on Sunday, June 20 through Thursday, June 25 at the Metro Toronto Convention Centre. To learn more about their research and to hear from other top researchers and experts in thrombosis and haemostasis, register here for 2015 ISTH Congress.
# # #
About the ISTH
Founded in 1969, the International Society on Thrombosis and Haemostasis (ISTH) is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The ISTH is an international membership organization with nearly 4,000 clinicians, researchers and educators working together to improve the lives of patients in more than 90 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and conferences, peer-reviewed publications and expert committees. Visit ISTH online at www.isth.org or call the ISTH at 1 (919) 929 3807.
Media Contact: Beth Campus
Tech Image (for ISTH)